Will the FDA revise its stance on synthetic botanical constituents? It’s not looking promising…
Firms hoping the FDA might change its unpopular stance on synthetic copies of botanical constituents as it rewrites its draft guidance on new dietary ingredients (NDIs) could be disappointed.